| pubmed-article:21047828 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21047828 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:21047828 | lifeskim:mentions | umls-concept:C0041296 | lld:lifeskim |
| pubmed-article:21047828 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:21047828 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:21047828 | lifeskim:mentions | umls-concept:C0035608 | lld:lifeskim |
| pubmed-article:21047828 | lifeskim:mentions | umls-concept:C0132326 | lld:lifeskim |
| pubmed-article:21047828 | lifeskim:mentions | umls-concept:C0332173 | lld:lifeskim |
| pubmed-article:21047828 | lifeskim:mentions | umls-concept:C1548602 | lld:lifeskim |
| pubmed-article:21047828 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:21047828 | pubmed:dateCreated | 2010-12-21 | lld:pubmed |
| pubmed-article:21047828 | pubmed:abstractText | rifampicin lowers nevirapine plasma concentrations by inducing cytochrome P450. However, few data are available on this interaction during the lead-in period of nevirapine treatment. | lld:pubmed |
| pubmed-article:21047828 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21047828 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21047828 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21047828 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21047828 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21047828 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21047828 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21047828 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21047828 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:21047828 | pubmed:issn | 1460-2091 | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:BoffitoMartaM | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:ColebundersRo... | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:BackDavidD | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:MerryConcepta... | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:RyanMairinM | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:KhooSayeS | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:Byakika-Kibwi... | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:LamordeMohamm... | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:KalemeeraFran... | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:Okaba-KayomVi... | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:NamakulaRhoda... | lld:pubmed |
| pubmed-article:21047828 | pubmed:author | pubmed-author:CoakleyPeterP | lld:pubmed |
| pubmed-article:21047828 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21047828 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:21047828 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21047828 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21047828 | pubmed:pagination | 180-3 | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:meshHeading | pubmed-meshheading:21047828... | lld:pubmed |
| pubmed-article:21047828 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21047828 | pubmed:articleTitle | Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. | lld:pubmed |
| pubmed-article:21047828 | pubmed:affiliation | Research Department, Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. mlamorde@idi.co.ug | lld:pubmed |
| pubmed-article:21047828 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21047828 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21047828 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
